MKI67 and breast carcinoma: In the neoadjuvant setting, Ki-67 can be used as a surrogate of pCR to monitor treatment response and thus tailor decision-making in HR+/HER2− breast cancer, as in the IMPACT, POETIC, and WSG ADAPT HR+/HER2− trials (22–24).